Skip to main content
Log in

Nephrotoxicity and Hepatotoxicity of Histamine H2 Receptor Antagonists

  • Review Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

The extensive use of selective histamine H2 receptor antagonists provides a unique opportunity to describe very rare adverse drug reactions.

Although mild elevation of serum creatinine level following the administration of cimetidine is relatively common, acute interstitial nephritis (AIN) is a rare hypersensitivity reaction. There have been 25 published reports of AIN associated with H2 antagonist therapy and we also identified 16 cases from the Australian Adverse Drug Reaction Advisory Committee (ADRAC) database. AIN was reported most commonly following cimetidine administration. AIN was supported by renal biopsy in 28 patients and by rechallenge in 6. H2 antagonist—induced AIN was more commonly reported in men older than 50 years. In the majority of cases the onset was within 2 weeks of initiation of therapy (1 day to 11 months). The clinical manifestations were nonspecific including sterile pyuria, elevated erythrocyte sedimentation rate, fatigue, proteinuria and leucocytosis whereas rash, arthralgia and flank pain were rarely reported.

There were 170 cases of hepatotoxicity following H2 antagonist administration reported to ADRAC. These were more common following ranitidine and included cholestatic, hepatocellular and mixed reactions. Hepatotoxicity was proven following liver biopsy in several cases published in the literature and in 15 cases reported to ADRAC. Hepatotoxicity recurred upon rechallenge in 6 cases.

Generally, renal and hepatic adverse effects resolved quickly after cessation of H2 antagonist therapy and did not require specific treatment. Nephrotoxicity and hepatotoxicity following administration of an H2 antagonist is rare and a high index of suspicion is necessary for early detection. Now that many H2 antagonists are available over the counter, awareness of these conditions and early detection with cessation of H2 antagonist therapy would appear paramount.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Table 1
Table II
Table II
Fig. 3
Table IV
Fig. 4

Similar content being viewed by others

References

  1. Folkow B, Haeger K, Kahlson G. Observations on reactive hyperaemia as related to histamine, on drugs antagonising vasodilation induced by histamine and on vasodilator properties of adenosine triphosphate. Acta Physiol Scand 1948; 15: 264–78

    Article  CAS  Google Scholar 

  2. Black JW, Duncan WAM, Durant GJ, et al. Definition and antagonism of histamine H2-receptors. Nature 1972; 236: 385–90

    Article  PubMed  CAS  Google Scholar 

  3. Duncan WAM, Parsons ME. Reminiscenses of the development of cimetidine. Gastroenterology 1980; 78: 620–25

    PubMed  CAS  Google Scholar 

  4. Freston JW. Cimetidine. Developments, pharmacology, and efficacy. Ann Intern Med 1982; 97: 573–80

    PubMed  CAS  Google Scholar 

  5. Gantz I, Schaffer M, DelValle J, et al. Molecular cloning of a gene encoding the histamine H2 receptor. Proc Natl Acac Sci 1991; 88: 429–33

    Article  CAS  Google Scholar 

  6. Hersey SJ, Sachs G. Gastric acid secretion. Physiol Rev 1995; 75: 155–90

    PubMed  CAS  Google Scholar 

  7. Dell Valle J, Gantz I. Novel insights into histamine H2 receptor biology. Am J Physiol 1997; 273: G 987–96

    Google Scholar 

  8. Brimblecombe RW, Duncan WAM, Durant GJ. Characterization and development of cimetidine as a histamine H2-receptor antagonist. Gastroenterology 1978; 74: 339–47

    PubMed  CAS  Google Scholar 

  9. Hirschowitz BI. H2 histamine receptors. Ann Rev Pharmacol Toxicol 1979; 19: 203–44

    Article  CAS  Google Scholar 

  10. Blackwood WS, Maudgal DP, Pickard RG. Cimetidine in duodenal ulcer. Lancet 1976; II: 174–6

    Article  Google Scholar 

  11. Freston JW. Cimetidine: adverse reactions and patterns of use. Ann Intern Med 1982; 97: 728–34

    PubMed  CAS  Google Scholar 

  12. Kruss DM, Littman A. Safety of cimetidine. Gastroenterology 1978; 74: 478–83

    PubMed  CAS  Google Scholar 

  13. Schunack W. What are the differences between the H2-receptor antagonists? Aliment Pharmacol Ther 1987; 1: 493S–503S

    Article  PubMed  CAS  Google Scholar 

  14. Zeldis JB, Friedman L, Isselbacher KJ. Ranitidine: a new H2-receptor antagonist. N Engl J Med 1983; 309: 1368–73

    Article  PubMed  CAS  Google Scholar 

  15. Vial T, Goubier C, Bergeret A, et al. Side effects of ranitidine. Drug Saf 1991; 6: 94–117

    Article  PubMed  CAS  Google Scholar 

  16. Gifford LM, Aeugle ME, Myerson RM, et al. Cimetidine postmarket outpatient surveillance program: interim report on phase 1. JAMA 1980; 243: 1532–5

    Article  PubMed  CAS  Google Scholar 

  17. Haggie SJ, Fermont DC, Wylie JH. Treatment of duodenal ulcer with cimetidine. Lancet 1976; I: 983

    Article  Google Scholar 

  18. Burland WL, Gleadle RI, Mills JG. Proceedings of the Second International Symposium of Histamine H2-Receptor Antagonists. In: Burland WL, Simkins MA, editors. Exerpta Medica: Amsterdam and Oxford, 1977: 67–73

  19. Larsson R, Bodemar G, Kagedal B. The effect of cimetidine, a new histamine H2-receptor antagonist, on renal function. Acta Medica Scand 1979; 205: 87–9

    Article  CAS  Google Scholar 

  20. Davis TG, Pickett DL, Schlosser JH. Evaluation of a worldwide spontaneous reporting system with cimetidine. JAMA 1980; 243: 1912–4

    Article  PubMed  CAS  Google Scholar 

  21. Handa SP. Drug-induced acute interstitial nephritis: report of 10 cases. Can Med Assoc J 1986; 135: 1278–82

    CAS  Google Scholar 

  22. Linton AL, Clark WF, Driedger AA, et al. Acute interstitial nephritis due to drugs. Ann Intern Med 1980; 93: 735–41

    PubMed  CAS  Google Scholar 

  23. Droz D, Kleinknecht D. In: Davison AM, Cameron JS, Grünfeld JP, et al, editors. Oxford textbook of clinical nephrology. 2nd edition. New York (NY): Oxford University Press, 1998: Vol 2, 1634–48

    Google Scholar 

  24. Black M. Hepatotoxic and hepatoprotective potential of histamine (H2) receptor antagonists. Am J Med 1987; 83(6A): 68–75

    Article  PubMed  CAS  Google Scholar 

  25. Van Steenbergen W, Vanstapel MJ, Desmet V, et al. Induced liver injury. Report of three cases. J Hepatol 1985; 1: 359–68

    Article  PubMed  Google Scholar 

  26. Bodemar G, Walan A. Maintenance treatment of recurrent peptic ulcer by cimetidine. Lancet 1978; I: 403–7

    Article  Google Scholar 

  27. Dutt MK, Moody P, Northfield TC. Effect of cimetidine on renal function in man. Br J Clin Pharmacol 1981; 12: 47–50

    Article  PubMed  CAS  Google Scholar 

  28. Burgess E, Blair A, Krichman K. Inhibition of renal creatinine secretion by cimetidine in humans. Renal Physiol 1982; 5: 27–30

    PubMed  CAS  Google Scholar 

  29. Sharpe PC, Hawkins BW. Proceedings of the Second International Symposium of Histamine H2-Receptor Antagonists. In: Burland WL, Simkins MA, editors. Exerpta Medica: Amsterdam, 1977: 358–66

  30. Kimberly RP, Weinberg H, Rudd E. Great reduction in renal function associated with cimetidine. Arthritis Rheumatol 1980; 23: 614

    Article  CAS  Google Scholar 

  31. Dubb JW, Stote RM, Familiar RG, et al. Effect of cimetidine on renal function in normal man. Clin Pharmacol Ther 1978; 24: 76–83

    PubMed  CAS  Google Scholar 

  32. McKinney TD, Myers P, Speeg KV. Cimetidine secretion by rabbit renal tubules in vitro. Am J Physiol 1981; 241: F69–76

    PubMed  CAS  Google Scholar 

  33. Czuba MA, Morgan DJ, Ching MS, et al. Ontogeny of fetal renal organic cation excretion: A study with cimetidine and ranitidine during the latter half of gestation in pregnant ewe. J Pharmacol Exp Ther 1990; 255: 1177–82

    PubMed  CAS  Google Scholar 

  34. Rocci ML, Vlasses PH, Ferguson RK. Creatinine serum concentrations and H2-receptor antagonists. Clin Nephrol 1984; 22: 214–5

    PubMed  Google Scholar 

  35. Pachon J, Lorber MI, Bia M. Effects of H2-receptor antagonists on renal function in cyclosporin-treated renal transplant patients. Transplantation 1989; 47: 254–9

    Article  PubMed  CAS  Google Scholar 

  36. Neelakantappa K, Gallo GR, Lowenstein J. Ranitidineassociated interstitial nephritis and Fanconi syndrome. Am J Kidney Dis 1993; 22: 333–6

    PubMed  CAS  Google Scholar 

  37. Kirch W, Hoensch H, Janisch HD. Interactions and non-interactions with ranitidine. Clin Pharmacokinet 1984; 9: 493–510

    Article  PubMed  CAS  Google Scholar 

  38. Feldman M, Burton ME. Histamine-2-receptor antagonists. Standard therapy for acid-peptic diseases. N Engl J Med 1990; 323: 1672–80

    Article  PubMed  CAS  Google Scholar 

  39. Selkurt EE. Influence of histamine on electrolyte and water handling of the canine kidney. Proc Soc Exp Biol Med 1977; 155: 605–10

    PubMed  CAS  Google Scholar 

  40. Selkurt EE, Hockel GM, Weinberger MH. Some evidence for interrelationship of histamine and prostaglandin on renal function. Proc Soc Exp Biol Med 1979; 160: 328–34

    PubMed  CAS  Google Scholar 

  41. Morley JJ, Ballou SP. Cimetidine-induced elevation of serum creatinine in a patient with lupus nephritis. J Rheumatol 1983; 10: 520–22

    PubMed  CAS  Google Scholar 

  42. McGowan WR, Vermillion SE. Acute interstitial nephritis related to cimetidine therapy. Gastroenterology 1980; 79: 746–49

    PubMed  CAS  Google Scholar 

  43. Hake DH. Interstitial nephritis and cimetidine. Ann Intern Med 1981; 94: 416

    PubMed  CAS  Google Scholar 

  44. Richman AV, Narayan JL, Hirschfield JS. Acute interstitial nephritis and acute renal failure associated with cimetidine therapy. Am J Med 1981; 70: 1272–4

    Article  PubMed  CAS  Google Scholar 

  45. Rudnick MR, Bastl CP, Elfenbein IB, et al. Cimetidine-induced renal failure. Ann Intern Med 1982; 96: 180–2

    PubMed  CAS  Google Scholar 

  46. Payne CR, Ackrill P, Ralston AJ. Acute renal failure and rise in alkaline phosphatase activity caused by cimetidine. BMJ 1982; 285: 100

    Article  PubMed  CAS  Google Scholar 

  47. Ali N, Hamilton DV, Pryor JS, et al. Safety of cimetidine. BMJ 1985; 291: 1426–7

    Article  PubMed  CAS  Google Scholar 

  48. Pitone JM, Sautoro JJ, Biondi RJ, et al. Cimetidine-induced acute interstitial nephritis. Am J Gastroenterol 1982; 77: 169–71

    PubMed  CAS  Google Scholar 

  49. Potter PH, Westby RG. Interstitial nephritis after cimetidine but not ranitidine. JAMA 1983; 249: 351

    Article  PubMed  Google Scholar 

  50. Kaye WA, Passero MA, Solomon RJ, et al. Cimetidine-induced interstitial nephritis with response to prednisone therapy. Arch Intern Med 1983; 143: 811–2

    Article  PubMed  CAS  Google Scholar 

  51. Watson AJS, Dalbow MH, Stachura I, et al. Immunologic studies in cimetidine-induced nephropathy and polymyositis. N Engl J Med 1983; 308: 142–5

    Article  PubMed  CAS  Google Scholar 

  52. Ozawa TT, Smith P, Vance D, et al. Acute interstitial nephritis induced by cimetidine. J Tenn Med Assoc 1987; 80: 411–3

    PubMed  CAS  Google Scholar 

  53. Mullen PJ. Polyuria and weight-loss associated with cimetidine. Postgrad Med J 1992; 68: 771

    Article  PubMed  CAS  Google Scholar 

  54. Koarada S, Nagano Y, Sakemi T et al. Acase of acute interstitial nephritis and nonoliguria acute renal failure induced by cimetidine [in Japanese]. Nippon Jinzo Gakkai Shi 1992; 34(11); 1227–32

    PubMed  CAS  Google Scholar 

  55. Kitahara T, Hiromura K, Sugawara M, et al. Acase of cimetidineinduced acute tubulointerstitial nephritis associated with antineutrophil cytoplasmic antibody. Am J Kidney Dis 1999; 33: E7

    Article  PubMed  CAS  Google Scholar 

  56. Freeman HJ. Ranitidine-associated interstitial nephritis in a patient with celiac sprue. Can J Gastroenterol 1988; 2: 35–6

    Google Scholar 

  57. Gaughan WJ, Sheth VR, Francos GC, et al. Ranitidine-induced acute interstitial nephritis with epithelial cell foot process fusion. Am J Kidney Dis 1993; 22: 337–40

    PubMed  CAS  Google Scholar 

  58. Karras DJ. Severe low back pain secondary to acute interstitial nephritis following administration of ranitidine. Am J Emerg Med 1994; 12: 67–8

    Article  PubMed  CAS  Google Scholar 

  59. Hirayama K, Hanatsuka K, Ikeuchi T, et al. Famotidine-induced acute interstitial nephritis. Nephrol Dial Transplant 1998; 13: 2636–8

    Article  PubMed  CAS  Google Scholar 

  60. Ooi BS, Jao W, First MR. Acute interstitial nephritis. Am J Med 1975; 59: 614–29

    Article  PubMed  CAS  Google Scholar 

  61. Galpin JE, Shinaberger JH, Stanley TM, et al. Acute interstitial nephritis due to methicillin. Am J Med 1978; 65: 756–65

    Article  PubMed  CAS  Google Scholar 

  62. Nolan CRI, Anger MS, Kelleher SP. Eosinophiluria: a new method of detection and definition of the clinical spectrum. N Engl J Med 1986; 315: 1516–9

    Article  PubMed  Google Scholar 

  63. Ruffing KA, Hoppes P, Blend D, et al. Eosinophils in urine revisited. Clin Nephrol 1994; 41: 163–6

    PubMed  CAS  Google Scholar 

  64. Katz SM, Capaldo R, Everts EA, et al. Association with reversible renal failure and acute interstitial nephritis. JAMA 1982; 246: 243–5

    Article  Google Scholar 

  65. Abraham PA, Keane WF. Glomerular and interstitial disease induced by nonsteroidal anti-inflammatory drugs. Am J Nephrol 1984; 4: 1–6

    Article  PubMed  CAS  Google Scholar 

  66. Shibata M, Hoon D, Okun E, et al. Modulation of histamine type receptors on CD8+T cells by interleukin-2 and cimetidine. Int Arch Allergy Immunol 1992; 97: 8–16

    Article  PubMed  CAS  Google Scholar 

  67. Hellstrand K, Asea A, Hermodsson S. Histaminergic regulation of antibody-dependent cellular cytotoxicity of granulocytes, monocytes, and natural killer cells. J Leucocyte Biol 1994; 55: 392–7

    CAS  Google Scholar 

  68. Hahm KB, Kim WH, Lee SI, et al. Comparison of immunomodulative effects of the histamine -2 receptor antagonists cimetidine, ranitidine, and famotidine on peripheral blood mononuclear cells in gastric cancer patients. Scand J Gastroenterol 1995; 30: 265–71

    Article  PubMed  CAS  Google Scholar 

  69. Hahm KB, Park IS, Kim HC, et al. Comparison of antiproliferative effects of the histamine-2 receptor antagonists, cimetidine, ranitidine, and famotidine, in gastric cancer cells. Int J Immunopharmacol 1996; 18: 397–9

    Article  Google Scholar 

  70. Fujimoto M, Kimata H. Histamine inhibits immunoglobulin production via histamine H2 receptors without affecting cell growth in human-cells. Clin Immunol Immunopathol 1994; 73: 96–102

    Article  PubMed  CAS  Google Scholar 

  71. Burton C, Scheinmann P, Fray A, et al. Ranitidine. N Engl J Med 1984; 310: 1603

    Google Scholar 

  72. Elenkov IJ, Webster E, Papanicolaou DA, et al. Histamine potently suppresses human L-12 and stimulates L-10 production via H2 receptors. J Immunol 1998; 161: 2586–93

    PubMed  CAS  Google Scholar 

  73. Kumar A. Cimetidine: an immunomodulator. Drug Intel Clin Pharm 1990; 24: 289–95

    CAS  Google Scholar 

  74. Gifford RR, Tilberg AF. Histamine type-2 receptor antagonist immune modulation. Cimetidine and ranitidine increase interleukin-2 production. Surgery 1987; 102: 242–7

    PubMed  CAS  Google Scholar 

  75. Katoh J, Kouji T, Sato W, et al. Cimetidine and immunoreactivity. Lancet 1996; 348: 404–5

    Article  PubMed  CAS  Google Scholar 

  76. Adams WJ, Morris DL. Pilot study: cimetidine enhances lymphocyte infilltration of human colorectal carcinoma: results of a small randomized control trial. Cancer 1997; 80: 15–21

    Article  PubMed  CAS  Google Scholar 

  77. Anlar B, Gucuyener K, Imir T. Cimetidine as an immunomodulator in subacute sclerosing panencephalitis: a double-blind, placebo-controlled study. Pediatr Infect Dis J 1993; 12: 578–81

    Article  PubMed  CAS  Google Scholar 

  78. Estelle F, Simons R. Principles and practice. In: Middleton E, editor. Allergy. Mosby: St Louis, 1998: 612–37

    Google Scholar 

  79. Matthiesen L, Berg G, Ernerudh J, et al. Lymphocyte subset and mitogen stimulation of blood lymphocytes in preeclampsia. Am J Reprod Immunol 1999; 41: 192–203

    Article  PubMed  CAS  Google Scholar 

  80. Adler SG, Cohen AH, Border WA. Hypersensitivity phenomena and the kidney: role of drugs and enviromental agents. Am J Kidney Dis 1985; 5: 75–96

    PubMed  CAS  Google Scholar 

  81. Knapp AB, Grimshaw RS, Goldfarb JP. Cimetidine-induced anaphylaxis. Ann Intern Med 1982; 97: 138–40

    Google Scholar 

  82. Hiraide A, Yoshioka T, Ohshima S. gE -mediated drug fever due to histamine H2-receptor blockers. Drug Saf 1990; 5: 455–7

    Article  PubMed  CAS  Google Scholar 

  83. Almroth G, Enestrom S, Hed J, et al. Autoantibodies to leucocyte antigens in hydralazine-associated nephritis. J Intern Med 1992; 231: 37–42

    Article  PubMed  CAS  Google Scholar 

  84. Singer S, Parry RG, Deodhar HA, et al. Acute interstitial nephritis, omeprazole and autineutrophil cytoplasmic antibodies. Clin Nephrol 1994; 42: 280

    PubMed  CAS  Google Scholar 

  85. Shih DJ, Korbet SM, Rydel JJ, et al. Renal vasculitis associated with ciprofloxacin. Am J Kidney Dis 1995; 26: 516–9

    Article  PubMed  CAS  Google Scholar 

  86. Avella J, Binder HJ, Madsen JE, et al. Effect of histamine H2-receptor antagonists on delayed hypersensitivity. Lancet 1978; I: 624–6

    Article  Google Scholar 

  87. Daman LA, Rosenberg EW. Acquired tolerance to dinitro-chlorobenzene reversed by cimetidine. Lancet 1977; II: 1087

    Article  Google Scholar 

  88. Jorizzo JL, Sams WM, Jegasothy BU. Cimetidine as an immunomodulator: chronic mucocutaneous candidiasis as a model. Ann Intern Med 1980; 92: 192–5

    PubMed  CAS  Google Scholar 

  89. Rocklin RD. Modulation of cellular immune responses in vivo and in vitro by histamine receptor bearing lymphocytes. J Clin Invest 1976; 57: 1051–8

    Article  PubMed  CAS  Google Scholar 

  90. Van Zwieten MJ, Leber PD, Bhan AK, et al. Experimental cellmediated interstitial nephritis with exogenous antigens. J Immunol 1977; 118: 589–93

    PubMed  Google Scholar 

  91. McCluskey RT, Bhan AK. Cell-mediated immunity in renal disease. Human Pathol 1986; 17: 146–53

    Article  CAS  Google Scholar 

  92. McCluskey RT, Colvin RB. Immunological aspects of renal tubular and interstitial diseases. Ann Rev Med 1978; 29: 191–203

    Article  PubMed  CAS  Google Scholar 

  93. Husby G, Tung KSK, Williams Jr RC. Characterization of renal tissue lymphocytes in patients with interstitial nephritis. Am J Med 1981; 70: 31–8

    Article  PubMed  CAS  Google Scholar 

  94. Stachura I, Jayakumar S, Bourke E. T and B lymphocyte subsets in fenoprofen nephropathy. Am J Med 1983; 75: 9–16

    Article  PubMed  CAS  Google Scholar 

  95. Stachura I, Si L, Madan E, et al. Mononuclear cell subsets in human renal disease enumeration in tissue sections with monoclonal antibodies. Clin Immunol Immunopathol 1984; 30: 362–73

    Article  PubMed  CAS  Google Scholar 

  96. Pamukcu R, Moorthy AV, Singer JR, et al. Idiopathic acute interstitial nephritis: characterization of the infiltrating cells in the renal interstitium as T helper lymphocytes. sAm J Kidney Dis 1984; 4: 24–9

    CAS  Google Scholar 

  97. Boucher A, Droz D, Adafer E, et al. Characterization of mononuclear cell subsets in renal cellular interstitial infiltrates. Kidney Int 1986; 29: 1043–9

    Article  PubMed  CAS  Google Scholar 

  98. Evans RL, Faldetta TJ, Humphreys RE, et al. Peripheral human T cells sensitized in mixed leukocyte culture synthesize and express Ia-like antigens. J Exp Med 1978; 148: 1440–5

    Article  PubMed  CAS  Google Scholar 

  99. Laberke H-G. Treatment of acute interstitial nephritis. Klin Wochenschr 1980; 58: 531–2

    Article  PubMed  CAS  Google Scholar 

  100. Pusey CD, Saltissi D, Bloodworth L, et al. Drug associated acute interstitial nephritis: clinical and pathological features and the response to high dose steroid therapy. Q J Med 1983; 52: 194–211

    PubMed  CAS  Google Scholar 

  101. Zimmerman HJ, Jacob L, Bassan H, et al. Effects of H2-blocking agents in hepatcytes in vitro: correlation with potential for causing hepatic disease in patients. Proc Soc Exp Biol Med 1986; 182: 511–4

    PubMed  CAS  Google Scholar 

  102. Willson RA, Hall T, Hart J. Oxmetidine (H2 receptor antagonist) induced cytotoxicity in isolated rat hepatocytes. J Appl Toxicol 1988; 8: 223–5

    Article  PubMed  CAS  Google Scholar 

  103. Andrade RJ, Lucena MI, Martin-Vivaldi R, et al. Acute liver injury associated with the use of ebrotidine, a new H2-receptor antagonist. J Hepatol 1999; 31: 641–6

    Article  PubMed  CAS  Google Scholar 

  104. Dobbs JH, Muir JG, Smith RN. H2-antagonists and hepatitis. Ann Intern Med 1986; 105: 803

    PubMed  CAS  Google Scholar 

  105. Rodriguez GLA, Wallander MA, Stricker BH. The risk of acute liver injury associated with cimetidine and other acid-suppressing anti-ulcer drugs. Br J Clin Pharmacol 1997; 43: 183–8

    Article  CAS  Google Scholar 

  106. Hirono S, Gohda E, Tsubouchi H, et al. Effect of histamine H2-receptor antagonists on DNA synthesis in adult rat hepatocytes in primary culture. Cimetidine enhanced hepatocytes proliferation stimulated with insulin and epidermal growth factor. Pharmacol Res Commun 1987; 19: 479–99

    Article  PubMed  CAS  Google Scholar 

  107. Delpre G, Kadish U, Livni E. Hepatitis following cimetidine administration. Am J Med Sci 1982; 283: 153–6

    Article  PubMed  CAS  Google Scholar 

  108. Lilly M, Hitch DC, Javitt NB. Cimetidine cholestatic jaundice in children. J Surg Res 1978; 24: 384–7

    Article  PubMed  CAS  Google Scholar 

  109. Villeneuve JP, Warner HA. Cimetidine hepatitis. Gastroenterology 1979; 77: 143–4

    PubMed  CAS  Google Scholar 

  110. Schwartz JT, Gyorkey F, Graham DY. Cimetidine hepatitis. J Clin Gastroenterol 1986; 8: 681–6

    Article  PubMed  CAS  Google Scholar 

  111. Boyd PT, Lepre F, Dickey JD. Chronic active hepatitis associated with cimetidine. BMJ 1989; 298: 324–5

    Article  PubMed  CAS  Google Scholar 

  112. Lorenzini I, Jezequel AM, Orlandi F. Cimetidine-induced hepatitis. Electron microscopic observations and clinical pattern of liver injury. Digest Dis Sci 1981; 26: 275–80

    Article  PubMed  CAS  Google Scholar 

  113. Cleator IGM. Adverse effects of ranitidine therapy. Can Med Assoc J 1983; 129: 405

    PubMed  CAS  Google Scholar 

  114. Proctor JD. Hepatitis associated with ranitidine. JAMA 1984; 251: 1554

    Article  PubMed  CAS  Google Scholar 

  115. Souza-Lima JAS. Hepatitis associated with ranitidine. Ann Intern Med 1984; 101: 207–8

    PubMed  CAS  Google Scholar 

  116. Offit K, Sojka DA. Ranitidine. N Engl J Med 1984; 310: 1603

    Google Scholar 

  117. Black M, Scott WE, Kanter R. Possible ranitidine hepatotoxicity. Ann Intern Med 1989; 101: 208–10

    Google Scholar 

  118. Barr GD, Piper DW. Possible ranitidine hepatitis. Med J Aust 1981; 2: 421

    PubMed  CAS  Google Scholar 

  119. Hiesse C, Cantarovich M, Santelli C, et al. Ranitidine hepatotoxicity in renal transplant patient. Lancet 1985; I: 1280

    Article  Google Scholar 

  120. Graham DY, Opekun AR, Smith JL, et al. Ranitidine and hepatotoxicity. Ann Intern Med 1985; 102: 416

    PubMed  CAS  Google Scholar 

  121. Lauritsen K, Havelund T, Rask-Madsen J. Ranitidine and hepatotoxicity. Lancet 1984; II: 1471

    Article  Google Scholar 

  122. Hegarty JE. Ranitidine and hepatotoxicity. Lancet 1985; I: 223

    Article  Google Scholar 

  123. Zeldis JB, Friedman LS, Isselbacher KJ. Ranitidine. N Engl J Med 1984; 310: 1605–6

    Article  Google Scholar 

  124. Jack D, Smith RN, Wise PJ. Ranitidine [letter]. N Engl J Med 1984; 310: 1606

    Article  Google Scholar 

  125. Devuyst D, Lefebvre C, Geubel A, et al. Acute cholestatic hepatitis with rash and hypereosinophilia. Acta Clin Belgium 1993; 48: 109–14

    CAS  Google Scholar 

  126. Karachalios GN. Ranitidine and hepatitis. Ann Intern Med 1985; 103: 634–5

    PubMed  CAS  Google Scholar 

  127. Ramrakhiani S, Brunt EM, Bacon BR. Possible cholestatic injury from ranitidine with a review of the literature. Am J Gastroenterol 1998; 93: 822–6

    Article  PubMed  CAS  Google Scholar 

  128. Dukes MNG. Meylers side effects of drugs. 13th edition. Amsterdam: Elsevier, 1996

    Google Scholar 

  129. Cherqui B, Desaint B, Legendre C, et al. Hepatite mortelle chez une patiente traitee par la ranitidine. Gastroenterol Clin Biol 1989; 13: 952–3

    PubMed  CAS  Google Scholar 

  130. Ribeiro J, Lucas M, Baptista A, et al. Fatal hepatitis associated with ranitidine. Am J Gastroenterol 2000; 95: 559–60

    PubMed  CAS  Google Scholar 

  131. Hashimoto F, Davis RL, Egli D. Hepatitis following treatments with famotidine and then cimetidine. Ann Pharmacother 1994; 28: 37–9

    PubMed  CAS  Google Scholar 

  132. Ament PW, Roth JD, Fox CJ. Famotidine-induced mixed hepatocellular jaundice. Ann Pharmacother 1994; 28: 40–2

    PubMed  CAS  Google Scholar 

  133. Lee sWM. Drug-induced hepatotoxicity. N Engl J Med 1995; 333: 118–27

    Article  Google Scholar 

  134. Farrell GC. Liver disease caused by drugs, anesthetics and toxins. In: Feldman M Scharschmidt BF, Sleisenger MH, editors. Sleiseuger and Fordtran’s gastrointestinal and liver disease. 6th ed. Philadelphia: W.B. Saunders Company, 1998: 1221–52

    Google Scholar 

  135. Maria VA, Victorino RM. Diagnostic value of specific T cell reactivity to drugs in 95 cases of drug indicued liver injury. Gut 1997; 41: 534–40

    Article  PubMed  CAS  Google Scholar 

  136. Cao J, Lu J, Wu F, et al. Effects of several drugs on the liver injury induced by delayed-type hypersensitvity to picryl chloride by regulating suppressor or helper T cells. Pharmacol Res 1999; 39: 97–102

    Article  PubMed  CAS  Google Scholar 

  137. Tyden G, Thulin L, Myberg B. The effect of cimetidine on liver blood flow in anesthetized men. Acta Chir Scand 1983; 149: 303–5

    PubMed  CAS  Google Scholar 

  138. Carfagna MA, Held SD, Kedderis GL. Furan-induced cytolethality in isolated rat hepatocytes: correspondence with in vivo dosimetry. Toxicol Appl Pharmacol 1993; 123: 265–73

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

We would like to thank Dr Patrick Purcell for information from the Australian Adverse Drug Reactions Advisory Committee (ADRAC), Dr Michael Falk for a case report, and Professor Allan J McLean, Professor Paul Gatenby and Kim Forsyth for assistance with the manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to David G. Le Couteur.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fisher, A.A., Le Couteur, D.G. Nephrotoxicity and Hepatotoxicity of Histamine H2 Receptor Antagonists. Drug-Safety 24, 39–57 (2001). https://doi.org/10.2165/00002018-200124010-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200124010-00004

Keywords

Navigation